MannKind’s Future Uncertain After Sanofi Terminates Afrezza Deal
This article was originally published in The Pink Sheet Daily
During a very brief investor call, MannKind says it is planning to change its pricing and contracting tactics, after being left in the lurch as Sanofi terminates its development and commercialization deal on the inhaled insulin Afrezza.
You may also be interested in...
FDA’s unusually specific request suggests continued worries about safety of MannKind’s inhalable insulin; large trial (8,000-10,000 type 2 diabetics) has a variety of goals.
The company is planning a direct-to-consumer education campaign to inform the public about the importance of vaccination.
The company showcased its pipeline in a two-day virtual meeting, trying to convince investors the long-term potential is undervalued.